The global dry eye syndrome market size was estimated at USD 5.8 Bn in 2021, growing at a CAGR of 5.1% during the forecast period 2021-2027. Dry eye syndrome (keratoconjunctivitis sicca), is an ocular disease caused by the lack of tear fluid to lubricate the eyes, which leads to problems in vision, tear film instability, and discomfort causes potential damage to the ocular surface. Dry eye syndrome can also cause due to other ocular surface diseases such as ocular allergy and meibomian gland dysfunction. The ocular surface contains 7 components including lacrimal and accessory lacrimal apparatus. Any abnormalities in one of the ocular surface components may cause the dry eye syndrome. Dry eye syndrome is classified into two types namely, evaporative dry eye and pure aqueous deficiency dry eye. The common symptoms associated with dry eye syndrome include ocular irritation, hyperaemia, mucoid discharge, blurred vision, excessive tearing, ocular dryness, photophobia, and grittiness. Dry eye syndrome is measured by a thin strip of filter paper placed at the edge of the eye, called a Schirmer test to measure the amount of tears present in the eye. Global dry eye syndrome treatment market is in the developing stage owing to increase in the research and development activities by the competitors in the dry eye syndrome treatment market. The patents of various dry eye syndrome treatment drugs are in expiry stage, so various pharmaceutical companies are actively involved in the R&D of new drugs. Some of the key strategies followed by various pharmaceutical companies to increase revenue share in global dry eye syndrome treatment market including acquisitions & mergers, collaborations, and launching of new products. For instance, in July 2013, Novaliq GmbH won European approval for its lubricating, drug-delivering eye drop NovaTears, designed for over-the-counter treatment of dry eye syndrome. Similarly, in June 2015,  Allergan plc, a pharmaceutical company acquired Oculeve Inc, a medical device company that focuses on new technologies for dry eye disease to improve market position in the dry eye syndrome treatment market. In addition, in January 2017, Novaliq announced the positive top-line results of phase 2 clinical trial evaluating CyclASol in adults with moderate to severe dry eye disease. Moreover, in October 2015, Allergan plc launched artificial tear Refresh Optive gel drops to provide artificial tear option to relieve dry eye symptoms.


Precision Business Insights, 5th Floor, Mohan’s Elite, Opp : Bharat Petroleum Pump, Khanamet Road, Hitech City, Hyderabad – 500084


Precision Business Insights, Kemp House, 152 – 160 City Road, London EC1V 2NX